BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has received ethics approval from the Royal Brisbane & Women’s Hospital, Human Research Ethics Committee for the Company’s planned Phase 2 Idiopathic Pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120

DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use

- Bank of America Global Research Health Care Conference on May 14 - RBC Capital Markets Global Healthcare Conference on May 19

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled “Composition and Method for Treating Colon Cancer with

AliveCor , the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, announced a strategic collaboration with the Clifford Lab at Emory University School of Medicine , and the Geor

Results published in CHEST Journal demonstrate benefits of using dynamic measures to guide fluid therapy decisions

Nascent Biotech, Inc (OTCQB: NBIO). On April 22, 2020, Nascent Biotech Inc. (the “Company”) notified Triton Funds, LLC (“Triton”) that it was cancelling their Stock Purchase Agreement (the “SPA”) and cancelled a purchase order dated April 15, 2020. The Company has discontinuing further draw downs on the equity line of credit with Triton. On April 27, 2020, the Company filed a Post-Effective Amendment to its Registration Statement filed with the Se

Better Visual Acuity, Reduced Geographic Atrophy (GA) Progression, and Improved Reading Speed Reported in First Cohort 4 and First Orbit SDS Patients Additional Interim Results from Phase I/IIa Clinical Study of OpRegen Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting Therapeutic Expert Call with Christopher D. Riemann, M.D. Scheduled for May 11, 2020 CARLSBAD, Calif.--( BUSINESS WIRE )-- Lineag

Titan Medical Inc. (“ Titan ” or the “ Company ”) ( TSX:TMD ) ( Nasdaq:TMDI ), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“ MIS ”), is pleased to announce today that it closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the p

While New York, New Jersey, Connecticut, and Massachusetts have provided medical liability immunity for their doctors treating COVID-19 patients, Pennsylvania Gov. Tom Wolf has remained silent on the issue.